Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
Healthy Volunteers
NCT06853340

Impact of Vascular Calcification and CASR Expression by Monocytes in Septic Shock

Led by Centre Hospitalier Universitaire, Amiens · Updated on 2025-04-25

66

Participants Needed

1

Research Sites

101 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

In septic shock, bacterial LPS is able to activate the CaSR of cardiomyocytes inducing their apoptosis in vitro. CaSR activation in monocytes is responsible for activation of the NLRP3 inflammasome and macropinocytosis. In front of this immune axis, a variation in the monocyte expression of the CaSR is expected in the state of shock. This is already observed in other pathologies such as renal failure or in animal models of severe burns. If this is considered as an overall reflection of CaSR expression in the body, it would be consistent with the phosphocalcic disturbances associated with septic shock. The phosphocalcic balance is often modified, and not treated during the acute episode, with in particular hypocalcaemia which could be consecutive to a hyperactivation or overexpression of the CaSR. This study proposes to explore for the first time the expression of monocytic CaSR in patients in a state of shock, with possible therapeutic perspectives by the existence of calcimimetics and calcilytics. In this study, the investigators propose to explore the CasR and its implication in septic shock in a three - part protocol : measurement by flow cytometry of monocyte expression of CASR (primary objective) and CD33, CD14, CD163, CD16 and HLA-DR), survey of clinical and biological parameters in patients with septic shock and healthy volunteers and acquisition of calcium score in patients with septic shock.

CONDITIONS

Official Title

Impact of Vascular Calcification and CASR Expression by Monocytes in Septic Shock

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female patients over the age of 18
  • Patients who have not participated in a study evaluating an investigational drug in the 30 days preceding the samples
  • Intensive care patients in a state of septic shock within the first 24 hours of the introduction of pressor amines
  • French resident year-round
  • Lactate > 2mmol/L
  • Patients with social security coverage
Not Eligible

You will not qualify if you...

  • Patients in hemorrhagic shock
  • History of parathyroidectomy or hypersecretion of PTHrp
  • Sarcoidosis
  • Genetic disturbances of CaSR including familial hypocalciuric hypercalcaemia
  • Current immunosuppressant treatment (anticalcineurin, mTOR inhibitor, methotrexate, high-dose corticosteroids excluding hydrocortisone and fludrocortisone)
  • Chronic myelomonocytic leukemia
  • Patients with febrile neutropenia
  • Patients with acquired or constitutional immune system disorders
  • Pregnant or breastfeeding patients
  • Patients under curatorship, guardianship, or safeguard of justice

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

CHRU Amiens

Amiens, France, 80480

Actively Recruiting

Loading map...

Research Team

Q

Quintana SOULIER

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

BASIC_SCIENCE

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here